Skip to main content
    G

    Gyre Therapeutics Inc. (GYRE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.39
    +0.08 (+1.86%)

    Market Cap: $471.74M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Gyre Therapeutics Inc. (GYRE) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Gyre Therapeutics are Neurogene (NGNE), Rocket Pharmaceuticals (RCKT) and Kyverna Therapeutics, Inc. Common Stock (KYTX). By market cap, Gyre Therapeutics ranks 6th of the 13 companies on this page; Geron (GERN) is the largest at $622.98M.

    Peer Comparison

    GYRE's revenue growth of 0.7% is above the peer median of -2.9%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Gyre Therapeutics (GYRE)$471.74MN/A3.8x-22.7%N/A0.7%0.00%
    Neurogene Inc (NGNE)$495.37MN/AN/A0.0%-28.5%0.0%0.00%
    Rocket Pharmaceuticals Inc (RCKT)$256.82MN/AN/A0.0%-2.3%0.0%0.00%
    Kyverna Therapeutics, Inc. Common Stock (KYTX)$319.27MN/AN/A0.0%-81.5%0.0%0.00%
    Prothena Corporation plc (PRTA)$419.01MN/A7.8x-45.4%N/A-74.3%0.00%
    Ginkgo Bioworks Holdings (DNA)$622.97MN/A6.1x-192.0%N/A-5.7%0.00%
    CytomX Therapeutics Inc (CTMX)$444.73MN/A31.0x0.0%-32.8%-71.7%0.00%
    Avalo Therapeutics Inc (AVTX)$448.71MN/AN/A0.0%N/A-69.3%0.00%
    Surrozen Inc (SRZN)$602.54MN/A36.1x0.0%N/A408.6%0.00%
    Tectonic Therapeutic, Inc. (TECX)$413.27MN/AN/A0.0%N/A0.0%0.00%
    Regenxbio Inc (RGNX)$505.18MN/A3.1x-113.9%N/A-69.2%0.00%
    Opus Genetics, Inc. (IRD)$384.68MN/A52.0x0.0%-145.1%-63.1%0.00%
    Geron Corporation (GERN)$622.98MN/A2.9x-22.0%-7.4%27.4%0.00%
    Peer median$446.72MN/A7.8x0.0%-30.6%-2.9%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Gyre Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Neurogene Inc (NGNE)
    Neurogene Inc. is an innovative biotechnology company at the forefront of developing advanced gene therapies for rare neurological disorders...
    NGNE competitors
    Rocket Pharmaceuticals Inc (RCKT)
    Rocket Pharmaceuticals, Inc., is a cross-platform biotechnology company focused on developing gene therapies for rare and devastating pediatric diseases.
    RCKT competitors
    Kyverna Therapeutics, Inc. Common Stock (KYTX)
    Kyverna Therapeutics, Inc. is an innovative biotechnology company focused on advancing immunotherapies for autoimmune diseases and other significant health...
    KYTX competitors
    Prothena Corporation plc (PRTA)
    Prothena Corporation plc, an advanced stage clinical company, is focused on the discovery and development of new therapies for life-threatening diseases...
    PRTA competitors
    Ginkgo Bioworks Holdings (DNA)
    Ginkgo Bioworks Holdings (DNA) is a pioneering force in synthetic biology, leveraging advanced genetic engineering to create customized bioengineered organisms...
    DNA competitors
    CytomX Therapeutics Inc (CTMX)
    CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company in the United States.
    CTMX competitors
    Avalo Therapeutics Inc (AVTX)
    Avalo Therapeutics Inc is a forward-thinking clinical-stage biotechnology company focused on developing transformative therapies for rare and underserved...
    AVTX competitors
    Surrozen Inc (SRZN)
    Surrozen Inc. is a clinical-stage biopharmaceutical company at the forefront of developing innovative therapeutics using its proprietary SIRPa-IgG platform...
    SRZN competitors
    Tectonic Therapeutic, Inc. (TECX)
    Tectonic Therapeutic, Inc. engages in the discovery of antibodies and other biologic drugs targeting G-protein-coupled receptors (GPCRs) to develop novel...
    TECX competitors
    Regenxbio Inc (RGNX)
    REGENXBIO Inc., a clinical-stage biotechnology company, offers candidate gene therapy products to deliver genes to cells to address genetic defects or to enable...
    RGNX competitors
    Opus Genetics, Inc. (IRD)
    Opus Genetics, Inc. (IRD) is a pioneering biotechnology company dedicated to advancing gene therapies for rare retinal diseases that affect vision.
    IRD competitors
    Geron Corporation (GERN)
    Geron Corporation, an advanced stage clinical biopharmaceutical company, focuses on the development and commercialization of therapies for myeloid hematologic...
    GERN competitors

    Frequently Asked Questions About GYRE

    Who are Gyre Therapeutics' main competitors?

    The companies most similar to Gyre Therapeutics include Neurogene (NGNE), Rocket Pharmaceuticals (RCKT), Kyverna Therapeutics, Inc. Common Stock (KYTX), Prothena Corporation (PRTA) and Ginkgo Bioworks Holdings (DNA), listed from the closest match.

    Who is Gyre Therapeutics' biggest competitor?

    Geron (GERN) is the largest of the similar companies at $622.98M; Neurogene (NGNE) is the closest match by business profile, size, sector and industry.

    How does GYRE stock compare with its competitors?

    GYRE's P/S is 3.8x against a peer median of 7.8x; its net margin is -22.7% against a peer median of 0.0%.

    Which of Gyre Therapeutics' competitors pays a higher dividend?

    Gyre Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Gyre Therapeutics bigger than its competitors?

    No. Gyre Therapeutics is 6th by market cap among the 13 companies on this page; the largest is Geron (GERN) at $622.98M.